Immunovant Inc. Common Stock vs Rubrik Inc. Class A Common Stock — how do they compare? Immunovant Inc. Common Stock trades at $30.25 (market cap $6.25B), while Rubrik Inc. Class A Common Stock trades at $122.1 (market cap $25.06B). The key difference: Rubrik Inc. Class A Common Stock is far larger — about 4× Immunovant Inc. Common Stock's market cap, and Rubrik Inc. Class A Common Stock is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Rubrik Inc. Class A Common Stock for 0 Days on average.
| IMVT | RBRK | |
|---|---|---|
Market Cap | $6.25B | $25.06B |
Volume | 1,755,411 | 2,394,852 |
Sector | Health | Technology |
52-Week High | $44.96 | $125.80 |
52-Week Low | $17.03 | $43.81 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $5.35B | $24.46B |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →Rubrik provides data security and cyber recovery software for enterprises. Its platform protects data across on-premises, cloud, SaaS, and unstructured-data environments.
Read more on RBRK →